

DOR BIOPHARMA INC
Form 8-K
July 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 9, 2004

DOR BioPharma, Inc.
(Exact name of registrant as specified in its charter)

<u>Delaware</u>	<u>0-8672</u>	<u>41-1505029</u>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<u>1691 Michigan, Suite 435, Miami, FL</u>		<u>33139</u>
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (305) 534-3383

Not applicable
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure

On July 9, 2004, the registrant announced that their CEO Ralph Ellison has resigned for personal reasons. A copy of the press release dated July 9, 2004 is filed herewith as Exhibit 99.1.

Exhibits

99.1 Press Release of DOR BioPharma, Inc regarding the Private Placement Financing

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DOR
	BioPharma,
	Inc.
Date:	By: <u>/s/Geoff</u>
July 13,	<u>Green</u>
2004	Geoff Green
	President

End of Filing